The mechanisms of the immunotherapeutic effects of MIDGE-Th1 encoding equine IL-12 and IL-18 demonstrated by Mählmann et al. [18] in grey horses affected with melanoma need to be elucidated in order to improve the directed clinical use of anti-tumour treatments. This evidence concerns the gene IL18 and melanoma.